OBJECTIVES: Although significant improvement in myasthenic symptoms has been reported following the removal of thymolipomas, information on surgical outcomes among patients with thymolipomatous myasthenia gravis (MG) is limited. METHODS: This was a retrospective review of patients who underwent extended thymectomy for treatment of MG. RESULTS: From 1995 to 2010, 267 patients with MG underwent extended thymectomy, including 104 with thymomatous MG, 151 with non-thymomatous MG and 12 (4.4%) with thymolipoma. The mean duration of myasthenic symptoms before surgery was greatest in the thymolipomatous group (P < 0.001). The lowest mean age (36.1 years old, P < 0.001) and the lowest preoperative serum anti-acetylcholine receptor antibody titre (P = 0.015) occurred in the non-thymomatous group. More thymic and adipose tissue was removed from the thymolipomatous group compared with the non-thymomatous group (P < 0.001). Regarding surgical outcomes, the rate of stable remission was higher in the non-thymomatous (42.3%) and thymolipomatous (41.7%) groups compared with the thymomatous group (28.8%, P = 0.029). No instances of postoperative exacerbation of MG or tumour recurrence were noted during the postoperative follow-up of patients treated for thymolipoma. CONCLUSIONS: Our results suggest that patients with myasthenia thymolipomatous have surgical outcomes similar to those of patients with non-thymomatous MG and have a mean age at the time of surgery similar to that of patients with thymomatous MG.
OBJECTIVES: Although significant improvement in myasthenic symptoms has been reported following the removal of thymolipomas, information on surgical outcomes among patients with thymolipomatous myasthenia gravis (MG) is limited. METHODS: This was a retrospective review of patients who underwent extended thymectomy for treatment of MG. RESULTS: From 1995 to 2010, 267 patients with MG underwent extended thymectomy, including 104 with thymomatous MG, 151 with non-thymomatous MG and 12 (4.4%) with thymolipoma. The mean duration of myasthenic symptoms before surgery was greatest in the thymolipomatous group (P < 0.001). The lowest mean age (36.1 years old, P < 0.001) and the lowest preoperative serum anti-acetylcholine receptor antibody titre (P = 0.015) occurred in the non-thymomatous group. More thymic and adipose tissue was removed from the thymolipomatous group compared with the non-thymomatous group (P < 0.001). Regarding surgical outcomes, the rate of stable remission was higher in the non-thymomatous (42.3%) and thymolipomatous (41.7%) groups compared with the thymomatous group (28.8%, P = 0.029). No instances of postoperative exacerbation of MG or tumour recurrence were noted during the postoperative follow-up of patients treated for thymolipoma. CONCLUSIONS: Our results suggest that patients with myasthenia thymolipomatous have surgical outcomes similar to those of patients with non-thymomatous MG and have a mean age at the time of surgery similar to that of patients with thymomatous MG.
Authors: Mohamed F Binfalah; Hussein H Alhafnawi; Ahmed A Jaradat; Eslam Shosha; Ali J Alhilly; Firas K Al Nidawi; Mariam M Alhammadi; Moiz O Bakhiet; Fatema M Abdulla Journal: Neurosciences (Riyadh) Date: 2022-01 Impact factor: 0.735
Authors: Zeead M Alghamdi; Sharifah A Othman; Mohammed Sabry Abdelmotaleb; Farouk Alreshaid; Abdullah Alomar; Mohammed Alaklbi; Hatem Y Elbawab; Yasser Aljehani Journal: Interact Cardiovasc Thorac Surg Date: 2022-03-31
Authors: Sharifah A Othman; Othman Y AlFrayyan; Zeead M AlGhamdi; Fahd Makhdom; Yasser AlJehani; Hatem Y Elbawab; Mohamed El-Shawarby Journal: Am J Case Rep Date: 2020-08-03